Alirocumab in the management of primary hypercholesterolaemia or mixed dyslipidaemia: A budget impact analysis – Italian perspective
Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish · 2018
DOI: 10.1177/2284240318781483 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish, 2018. Verfasst von Alessia Marocco und 4 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Marocco, A., Stanisic, S., Fanelli, F., Damele, F., & Colivicchi, F. (2018). Alirocumab in the management of primary hypercholesterolaemia or mixed dyslipidaemia: A budget impact analysis – Italian perspective. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. https://doi.org/10.1177/2284240318781483
Vancouver
Marocco A, Stanisic S, Fanelli F, Damele F, Colivicchi F. Alirocumab in the management of primary hypercholesterolaemia or mixed dyslipidaemia: A budget impact analysis – Italian perspective. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. 2018. doi:10.1177/2284240318781483
BibTeX
@article{Marocco2018,
author = {Marocco, Alessia and Stanisic, Sanja and Fanelli, Francesca and Damele, Francesco and Colivicchi, Furio},
title = {Alirocumab in the management of primary hypercholesterolaemia or mixed dyslipidaemia: A budget impact analysis – Italian perspective},
journal = {Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish},
year = {2018},
doi = {10.1177/2284240318781483}
}
EUVIMED